Mankind Pharma Acquires Indian Rights to Rivotril from Roche

Mankind Pharma, a New Delhi-based pharmaceutical company, has acquired the Indian rights to Rivotril, a well-established brand from Swiss giant Roche. This strategic move aims to strengthen Mankind's presence in chronic and central nervous system (CNS) therapies.

Key Highlights

• The deal grants Mankind Pharma exclusive rights to manufacture, market, and distribute Rivotril in India.
• Mankind Pharma stock was trading at Rs 2,121.90 on BSE at 11:04 am, up 2.63% from the previous close.
• Mankind Pharma is shifting its focus from traditional acute markets to specialty and chronic segments to keep pace with the industry-wide move beyond commoditized drugs.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Business Strategy

• Mankind Pharma aims to increase the contribution of chronic segments to its revenue mix through in-licensing deals, new launches, and portfolio additions.
• The company plans to leverage its nationwide distribution network and sizeable field force to widen the brand's reach across urban and semi-urban markets.
• Rivotril offers Mankind Pharma a ready-made leadership opportunity in a category that depends heavily on specialist trust and clinical legacy.

Market Opportunity

• Rivotril is considered a "textbook brand" in neurology with long-standing recall among psychiatrists and neurologists.
• The brand offers a defensible position in epilepsy, anxiety disorders, and other neurological conditions where clonazepam remains widely prescribed.
• Mankind Pharma sees scope for line extensions and expanded indications as it builds out a broader CNS platform.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year